Myeloma UK study of patient preferences published

Results from a Myeloma UK study, in which myeloma patients participated in a survey to determine individual preferences for treatment outcomes, have been published in The Oncologist. The survey, which was based on multicriteria decision analysis (MCDA) and swing weighting, asked patients to state their preference for the following outcomes of treatment; an increase in…

Details

Supportive treatments

Advances in the Treatment of Paraproteinemic Neuropathy. Nobile-Orazio E et al. Curr Treat Options Neurol. 2017 Oct 16;19(12):43. doi: 10.1007/s11940-017-0479-9. Effectiveness of IHD with Adsorptive PMMA Membrane in Myeloma Cast Nephropathy: A Cohort Study. Sens F et al. Am J Nephrol. 2017 Oct 10;46(5):355-363. doi: 10.1159/000481461. [Epub ahead of print]. Interbody distraction and vertebral body reconstruction with polymethylmethacrylate for the treatment of pathological…

Details

Related conditions

Elevation of Plasmin-α2-plasmin Inhibitor Complex Predicts the Diagnosis of Systemic AL Amyloidosis in Patients with Monoclonal Protein. Ishiguro K et al. Intern Med. 2017 Oct 11. doi: 10.2169/internalmedicine.8999-17. [Epub ahead of print]. Metachronous solitary plasmacytoma. Khosa R et al. BMJ Case Rep. 2017 Oct 19;2017. pii: bcr-2017-221780. doi: 10.1136/bcr-2017-221780. Intratubular amyloid in light chain cast nephropathy is a risk factor for…

Details

General

A Comparative Assessment of Quality of Life in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Martino M et al. Biol Blood Marrow Transplant. 2017 Oct 12. pii: S1083-8791(17)30764-4. doi: 10.1016/j.bbmt.2017.09.021. [Epub ahead of print]. Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the…

Details

Emerging treatments

Preclinical development of CD38-targeted [89Zr]Zr-DFO-daratumumab for imaging multiple myeloma. Ghai A et al. J Nucl Med. 2017 Oct 12. pii: jnumed.117.196063. doi: 10.2967/jnumed.117.196063. [Epub ahead of print]. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Kumar S et al. Blood. 2017 Oct 10. pii: blood-2017-06-788786. doi: 10.1182/blood-2017-06-788786. [Epub ahead of print]. Phase-I randomized trial of doxorubicin hydrochloride liposome injection versus…

Details